In new letter just posted, Gilead CEO says the company has ramped up remdesivir supply to 1.5 million individual doses (depending on optimal duration of treatment, which is being studied, could equate to 140K+ courses) which it’s providing to treat severe #COVID19 at no cost (1)
Gilead CEO Dan O’Day says company has set a goal of producing more than 500K treatment courses of remdesivir by October & 1M+ by year-end. Manufacturing remdesivir is a long process; O’Day says Gilead has reduced it from about a year to six months (2) #COVID19
Gilead CEO O’Day says doses of remdesivir are for treating #COVID19 patients w severe symptoms, daily IV infusions, in hospital setting. “Having a potential treatment in our hands comes with significant responsibility.” (3)
Gilead building “geographically diverse consortium” to increase capacity for raw materials, production. “The international nature of the supply chain for remdesivir reminds us that it is essential for countries to work together to create enough supply for the world.” (4)
Gilead CEO says the company has provided remdesivir to more than 1,700 #COVID19 patients through compassionate use, expanded access programs (5)
Gilead CEO: “These are intense, ongoing efforts and while they continue, we must await the data from the clinical trials before we know whether remdesivir is a safe and effective treatment.” #COVID19 gilead.com/stories/articl…
Deeper dive on Gilead’s remdesivir manufacturing and supply here: gilead.com/purpose/advanc… #COVID19 
